IGNE Stock Overview

Focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. More details

IGNE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($2K)

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Igene Biotechnology, Inc. Competitors

Plastec Technologies

OTCPK:PLTY.F

US$284.6k

N2OFF

NasdaqCM:NITO

US$12.8m

Enlightify

NYSE:ENFY

US$18.9m

Tantech Holdings

NasdaqCM:TANH

US$1.2m

Price History & Performance

Summary of share price highs, lows and changes for Igene Biotechnology
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	0%
3 Year Change	0%
5 Year Change	-99.75%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	IGNE	US Chemicals	US Market
7D	0%	-0.3%	0.6%
1Y	0%	5.3%	22.4%

Return vs Industry: IGNE underperformed the US Chemicals industry which returned 7.1% over the past year.

Return vs Market: IGNE underperformed the US Market which returned 22.7% over the past year.

Price Volatility

Is IGNE's price volatile compared to industry and market?
IGNE volatility
IGNE Average Weekly Movement	n/a
Chemicals Industry Average Movement	5.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.8%
10% least volatile stocks in US Market	3.2%

Stable Share Price: IGNE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IGNE's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1981	n/a	Joseph Downs	www.igene.com

Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, a nutrient used as a source of pigment for coloring farmed salmon and trout species. It also supplies ingredients and finished products to the nutraceutical and feed industry.

Igene Biotechnology, Inc. Fundamentals Summary

How do Igene Biotechnology's earnings and revenue compare to its market cap?
IGNE fundamental statistics
Market cap	US$1.56k
Earnings (TTM)	-US$2.37m
Revenue (TTM)	US$4.80k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is IGNE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IGNE income statement (TTM)
Revenue	US$4.80k
Cost of Revenue	-US$36.04k
Gross Profit	US$40.85k
Other Expenses	US$2.41m
Earnings	-US$2.37m

Last Reported Earnings

Sep 30, 2010

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did IGNE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/05 06:41
End of Day Share Price	2024/12/12 00:00
Earnings	2010/09/30
Annual Earnings	2009/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Igene Biotechnology, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.